



UNIVERSITI PUTRA MALAYSIA

***ANTIVIRAL EFFECT OF TRIPLE HELIX-FORMING
OLIGONUCLEOTIDES ON FELINE INFECTIOUS PERITONITIS VIRUS
INFECTION IN VITRO***

CHOONG OI KUAN

IB 2012 20

**ANTIVIRAL EFFECT OF TRIPLE HELIX-FORMING
OLIGONUCLEOTIDES ON FELINE INFECTIOUS PERITONITIS VIRUS
INFECTION *IN VITRO***

By

CHOONG OI KUAN

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,
in Fulfilment of the Requirements for the Degree of Master of Science
May 2012**

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Master of Science

**ANTIVIRAL EFFECT OF TRIPLE HELIX-FORMING
OLIGONUCLEOTIDES ON FELINE INFECTIOUS PERITONITIS VIRUS
INFECTION *IN VITRO***

By

CHOONG OI KUAN

May 2012

Chair: Abdul Rahman Omar, PhD

Faculty: Institute of Bioscience

Feline infectious peritonitis virus (FIPV) is a feline coronavirus (FCoV) which causes a fatal immune-mediated disease called feline infectious peritonitis (FIP) in cats. The virus is classified under the family *Coronaviridae* which consist of a positive sense single stranded RNA genome positioned in helical symmetry. FIPV has been proven as mutants of feline enteric coronavirus (FECV) where the main transmission route for this virus is through faecal-oral route which target the monocytes and macrophage cells. Antiviral chemotherapy treatments using Ribavirin and interferon have been used to treat the disease symptomatically. However, these treatments are not effective to control the fatal progression of the disease.

Furthermore, the various vaccines that have been developed are ineffective to control FIP in cats. Hence, the development of new effective therapy against FIP is impelled.

Triple Helix-Forming Oligonucleotide (TFO) were chosen as a potential anti-viral therapy to inhibit FIP replication due to its ability to compete successfully with other DNA/RNA binders and sequence-specific binding. Specific TFOs targeted to the selected regions of virulent feline coronavirus (FCoV) strain FIPV WSU 79-1146 genomes were designed and tested in FIPV infected Crandell-Reef Feline Kidney (CRFK) cell line. Five different circular TFOs (TFO1 to TFO5) and one unrelated circular TFO (TFO7) were designed and tested for *in vitro* antiviral effects. TFO1 and TFO2 target the 5' and 3' untranslated region (UTR) of FIPV genome, respectively, while the TFO3, TFO4 and TFO5 target the different regions of open reading frame (ORF) 1a/1b of FIPV genome.

Results revealed that TFO1, TFO3, TFO4 and TFO5 were able to hybridize to the target regions and produced triplex, while TFO2 was unable to perform hybridization with its target region. *In vitro* antiviral assays were conducted to examine the ability of TFOs to inhibit virus replication in cell culture based on the presence of CPE and quantitation of viral RNA genome using qRT-PCR. Results from this study showed 50 to 100 nM of circular TFO1 is sufficient to inhibit virus replication. However, increasing the concentration of TFO1 to 500 nM does not enhance the ability of the TFO to inhibit FIPV replication. In the study of antiviral effect of TFOs, results showed the copies of viral RNA genome of cells treated with TFO1, TFO2, TFO3,

TFO4, TFO5 and TFO7 are 3.65×10^9 , 2.23×10^{14} , 4.86×10^9 , 5.01×10^9 , 4.41×10^9 and 6.02×10^{14} , respectively. Hence, transfection with all the circular TFOs, except for TFO2 significantly reduced viral RNA genome up to 100,000 fold compared to mock transfected cells. As expected the mock transfected cells showed high copy number of viral RNA genome, 3.93×10^{14} . qRT-PCR study also showed that all linear TFOs and unrelated TFO7 were unable to show any antiviral properties towards the virus. In addition, circular TFO1 and TFO5 which effectively inhibit FIPV replication failed to show any antiviral properties in influenza virus subtype H1N1 infected cells.

In conclusion, all the circular TFOs except for TFO2 demonstrated antiviral effect on FIPV replication indicating the potential use of TFO as an antiviral agent against coronavirus such as FIPV in cats. Further studies are underway to demonstrate the therapeutic values of the designed TFOs towards FIPV infection in cats.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

**KESAN ANTIVIRAL OLIGONUKLEOTIDE YANG
MEMBENTUK HELIKS GANDAAN TIGA DENGAN VIRUS PERITONITIS
JANGKITAN FELIN IN VITRO**

Oleh

CHOONG OI KUAN

Mei 2012

Pengerusi: Abdul Rahman Omar, PhD

Fakulti: Institut Biosains

Virus peritonitis jangkitan felin (FIPV) adalah virus korona felin (FCoV) yang boleh menyebabkan peritonitis jangkitan felin (FIP) iaitu penyakit maut akibat tindak balas sistem imun di dalam kucing. Virus tersebut dikelaskan di bawah keluarga *Coronaviridae* dan mengandungi genom RNA untai tunggal polar positif yang berbentuk simetri heliks. FIPV merupakan mutan virus korona felin (FECV) dan laluan penularan utama bagi virus ini adalah melalui tinja yang menjadikan monosit dan sel makrofaj sebagai sasaran. Rawatan antiviral kemoterapi yang melibatkan Ribavirin dan interferon telah digunakan untuk merawat penyakit ini dengan berpandukan simptom yang ada pada kucing. Namun, rawatan ini tidak dapat mengawal perkembangan

penyakit tersebut dengan berkesan. Bahkan vaksin juga tidak dapat mengawal FIP dalam kucing. Oleh yang demikian, penemuan terapi baru yang lebih berkesan untuk menangani masalah ini amatlah diperlukan.

Oligonukleotida yang membentuk heliks gandaan tiga (TFO) telah dipilih sebagai terapi antivirus yang berpotensi untuk merencat replikasi FIPV oleh kerana kebolehan TFO untuk bersaing dengan pengikat DNA/RNA yang lain dan sifat pengikatan yang khusus dalam urutan genom. TFO khusus yang menasaskan kawasan tertentu dalam genom FECV strain virulen FIPV WSU 79-1146 telah direka dan diuji dalam sel Crandell-Reef Feline Kidney (CRFK) yang dijangkiti oleh FIPV. Lima TFO bulat yang berbeza (TFO1 sehingga TFO5) dan satu TFO bulat yang tidak berkaitan (TFO7) telah dicipta dan diuji untuk kesan antivirus *in vitro*. TFO1 dan TFO2 masing-masing menasaskan bahagian 5' dan 3' kawasan tidak diterjemahkan (UTR) dalam genom FIPV, manakala TFO3, TFO4 dan TFO5 menasaskan kawasan bacaan terbuka (ORF) 1a/1b bagi genom FIPV.

Keputusan menunjukkan TFO1, TFO3, TFO4 dan TFO5 mampu berinteraksi dengan sasaran masing-masing and membentuk gandaan tiga, manakala TFO2 tidak dapat melaksanakan hibridisasi dengan kawasan sasarannya. Kajian *in vitro* telah dijalankan untuk mengkaji keupayaan TFOs dalam menyekat replikasi virus di dalam kultur sel berdasarkan kehadiran CPE dan kuantifikasi genom RNA virus menggunakan qRT-PCR. Hasil daripada kajian ini menunjukkan 50 nM hingga 100 nM TFO1 bulat berupaya untuk menghalang replikasi virus. Walau bagaimanapun, peningkatan

kepekatan TFO1 kepada 500 nM tidak menambah keupayaan TFO untuk merencat replikasi FIPV. Untuk kajian kesan antiviral TFOs, keputusan menunjukkan bilangan salinan genom RNA virus bagi sel yang dirawat dengan TFO1, TFO2, TFO3, TFO4, TFO5 dan TFO7 masing-masing adalah 3.65×10^9 , 2.23×10^{14} , 4.86×10^9 , 5.01×10^9 , 4.41×10^9 and 6.02×10^{14} . Maka, transfeksi dengan kesemua TFO bulat kecuali TFO2 telah mengurangkan secara signifikan bilangan salinan genom virus RNA sehingga 100,000 kali berbanding sel transfeksi maya. Seperti yang dijangkakan, sel transfeksi kawalan menunjukkan bilangan salinan genom virus RNA yang tinggi iaitu 3.93×10^{14} . Kajian qRT-PCR juga menunjukkan bahawa semua TFO linear dan TFO7 bulat tidak dapat menunjukkan kesan antivirus terhadap FIPV. Selain itu, TFO1 dan TFO5 bulat yang merencat replikasi FIPV dengan berkesan gagal menunjukkan ciri antivirus di dalam sel yang dijangkiti dengan virus influenza subtipe H1N1.

Kesimpulannya, semua TFO bulat kecuali TFO2 menunjukkan kesan antivirus terhadap replikasi FIPV yang menandakan potensi penggunaan TFO sebagai agen antivirus terhadap virus korona seperti FIPV di dalam kucing. Kajian lanjutan sedang dijalankan untuk menguji nilai terapeutik TFO tersebut di dalam kucing yang dijangkiti FIPV.

ACKNOWLEDGEMENT

This thesis would not have been possible without the guidance and the help of several individuals who in one way or another contributed and extended their valuable assistance in the preparation and completion of this study.

First and foremost, I would like to express my warmest gratitude and appreciation to my supervisor, Prof. Dr. Abdul Rahman Omar whose sincerity and encouragement I will never forget. Prof Dr. Abdul Rahman Omar has been my inspiration as I hurdled all the obstacles in the completion of this research work. My deepest gratitude also goes to Dr. Bimo Ario Tejo for his constructive suggestions and consideration regarding my academic requirements.

Thanks to all postgraduates and officers of Laboratory of Vaccines and Immunotherapeutics of Institute of Bioscience for being accommodating to my queries. I would like to thanks to my friends who support me morally during my study. Special thanks goes to Parvaneh Mehrbod who assisted me in a part of my research.

I would like to acknowledge and thanks to the financial support of National Science Fellowship (NSF) from Ministry of Science, Technology and Innovation (MOSTI).

Last but not the least, I would like to express my highest appreciation and gratitude to my family. Thanks for their supports, concerns and encouragement during my study.



I certify that a Thesis Examination Committee has met on 21 May 2012 to conduct the final examination of Choong Oi Kuan on her thesis entitled “**Antiviral effect of triple helix-forming oligonucleotides on feline infectious peritonitis virus infection *in vitro***” in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U. (A) 106] 15 March 1998. The Committee recommends that the student be awarded the **degree of Master of Science**.

Members of the Thesis Examination Committee were as follows:

Sharida binti Fakurazi, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Zeenathul Nazariah binti Allaudin, PhD

Associate Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Internal Examiner)

Syahrilnizam bin Abdullah, PhD

Doctor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Internal Examiner)

Nicola Stonehouse, PhD

Doctor
Faculty of Biological Sciences
University of Leeds
UK
(External Examiner)

SEOW HENG FONG, PhD

Professor and Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:


This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

Abdul Rahman Omar, PhD

Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Chairman)

Bimo Ario Tejo, PhD

Senior Lecturer
Faculty of Science
Universiti Putra Malaysia
(Member)



BUJANG BIN KIM HUAT, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:

TABLE OF CONTENTS

	Page
ABSTRACT	ii
ABSTRAK	v
ACKNOWLEDGEMENTS	viii
APPROVAL	x
DECLARATION	xii
LIST OF TABLES	xvii
LIST OF FIGURES	xix
LIST OF ABBREVIATIONS	xxi
CHAPTER	
1 INTRODUCTION	
1.1 Background	1
1.2 Objectives	4
2 LITERATURE REVIEW	
2.1 Coronaviruses	5
2.2 Coronavirus RNA Replication and Transcription	6
2.2.1 Replicase-Transcriptase Proteins and Replicase-Transcriptase Complex	6
2.2.2 Model of Discontinuous RNA Synthesis	9
2.3 Feline Coronavirus (FCoV)	14
2.3.1 Biotypes	14
2.3.2 Serotypes	16
2.3.3 Genome of FIPV	17
2.3.4 Clinical Features Caused by FIPV	20
2.3.5 Treatment	21
2.4 Molecular Therapy	26
2.4.1 siRNA and miRNA	28
2.4.2 PNA	31
2.4.3 Aptamer	34
2.4.4 TFO	35
2.4.4.1 Purine Motif and Pyrimidine Motif	37
2.4.4.2 The Application of TFO	40
2.4.4.3 The Limitation of TFO	42

3	METHODOLOGY	
3.1	TFO Designation and Construction	43
3.2	RNA Oligonucleotide	46
	3.2.1 Synthesis of RNA Oligonucleotide	46
	3.2.2 Deprotection 2'-ACE Protected RNA	47
3.3	Circularization of Linear RNAs	48
3.4	Recovery of Circular RNAs	49
3.5	Spectrophotometry	50
3.6	Denaturing Urea PAGE	50
	3.6.1 Denaturing Urea PAGE Preparation	51
	3.6.2 Pre-run Denaturing Urea PAGE	52
	3.6.3 Sample Preparation	52
	3.6.4 Loading and Running Samples	53
	3.6.5 Gel Staining and Viewing	53
3.7	EMSA	54
	3.7.1 Hybridization of TFO with Targeted Gene Sequence	54
	3.7.2 Native Polyacrylamide Gel Preparation	55
	3.7.3 Loading and Running Samples	55
	3.7.4 Gel Staining and Viewing	56
3.8	Cell Culture	56
	3.8.1 Media Preparation	56
	3.8.2 Thawing and Sub-culturing Cells	57
	3.8.3 Cryopreservation	58
	3.8.4 Virus Propagation	58
	3.8.5 Detection of FIPV	59
	3.8.5.1 Viral RNA Extraction	59
	3.8.5.2 RT-PCR for FIPV Detection	60
	3.8.5.3 Agarose Gel Electrophoresis	61
	3.8.6 Cell Counting	62
	3.8.6.1 Cell Suspension Preparation	62
	3.8.6.2 Counting the Cells	63
	3.8.7 Quantitation of FIPV	64
3.9	Determination of the Effectiveness of Transfection Reagent Using RNA Labelled with Fluorescent Dye	65
3.10	<i>In Vitro</i> Study	66
	3.10.1 Cytotoxicity Study of Transfection Reagent	66

	towards CRFK Cells Using MTT Assay	
3.10.2	<i>In Vitro</i> Antiviral Effect of TFOs towards FIPV	67
3.10.3	Dose-response of TFO in Inhibiting FIPV Replication	68
3.10.4	The <i>In Vitro</i> Specificity Study of TFOs towards Influenza A Virus Subtype H1N1 New Jersey 8/76	69
3.10.5	qRT-PCR for FIPV Samples	70
3.10.6	qRT-PCR for H1N1 Samples	71
4	RESULTS AND DISCUSSION	
4.1	TFO Designation and Construction	73
4.2	Development of TFO against FIPV	77
4.3	Denatured PAGE	81
4.4	Electrophoretic Mobility Shift Assay (EMSA)	83
4.5	RT-PCR for FIPV Detection	86
4.6	Determination of FIPV Titer	87
4.7	Detection of Transfection Efficiency Using RNA Labelled with Fluorescent Dye	91
4.8	Cytotoxicity Study of Transfection Reagent towards CRFK Cells Using MTT Assay	94
4.9	Dose-response Study of TFO on FIPV replication	95
4.10	<i>In Vitro</i> Antiviral Effect of TFOs towards FIPV	96
4.11	<i>In Vitro</i> Specificity of TFOs towards Influenza A Virus	102
5	CONCLUSION AND RECOMMENDATIONS	
5.1	Conclusion	104
5.2	Recommendations	105
	REFERENCES	108

APPENDIX

I	Calculation Model for Reed-Muench Method	121
II	Flow Chart for Methodology	122
III	Bioinformatics Analysis for TFO1	123
IV	Bioinformatics Analysis for TFO4	124
V	Bioinformatics Analysis for TFO5	125
VI	Data for Cytotoxicity of Transfection Reagent	126
VII	Data for Dose-response Study	128
VIII	Data for <i>In Vitro</i> Antiviral Effect Study	129

BIODATA OF STUDENT

130

